ARS Pharmaceuticals, Inc.
Description
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
About
CEO
Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
Employees
24
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
11682 El Camino Real, San Diego, CA 92130, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 11, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| May 7, 2025 | — | — | — | — |
| Mar 19, 2025 | — | — | — | — |
| Nov 13, 2024 | -0.15 | -0.20 | -0.05 | 33.33% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 2 | — | 3 |
| Average estimate | — | -0.19 | — | -0.35 |
| Low estimate | — | -0.25 | — | -1.20 |
| High estimate | — | -0.12 | — | 0.60 |
| Last year EPS | — | -0.11 | — | -0.55 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-52.390%
Next qtr. (Mar 2025)
-68.180%
Current year
4.090%
Next year (Dec 2025)
36.590%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total reported revenue | 30,000 | 1.32M | 5.51M | 17.84M |
| Cost of revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating expense | ||||
| Research & development | 20.27M | 18.38M | 20.27M | 14.07M |
| Selling general and admin | 47.28M | 18.46M | 4.69M | 4.23M |
| Other operating expenses | — | — | — | — |
| Operating income | -67.52M | -35.52M | -19.45M | -469,000 |
| Non operating interest income | ||||
| Income | — | — | — | — |
| Expense | — | — | — | — |
| Other income expense | 13.16M | 834,000 | -789,000 | -596,000 |
| Pretax income | -54.37M | -34.68M | -20.24M | -1.07M |
| Tax provision | — | — | — | — |
| Net income | -54.37M | -34.68M | -20.24M | -1.07M |
| Basic EPS | -0.57 | -0.87 | -0.22 | -0.01 |
| Diluted EPS | -0.57 | -0.87 | -0.22 | -0.01 |
| Basic average shares | 95.22M | 39.96M | 93.77M | 93.77M |
| Diluted average shares | 95.22M | 39.96M | 93.77M | 93.77M |
| EBITDA | -67.52M | -35.06M | -19.24M | -463,000 |
| Net income from continuing op. | -54.37M | -34.68M | -20.24M | -1.07M |
| Minority interests | — | — | — | — |
| Preferred stock dividends | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 233.19M | 281.44M | 61.45M | 26.41M | 130.19M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 70.97M | 210.52M | 60.06M | 24.52M | 125.70M |
| Other short term investments | 157.39M | 63.86M | — | — | — |
| Accounts receivable | — | — | — | 380,000 | — |
| Other receivables | 109,000 | 213,000 | 1,000 | 4,000 | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | 2.41M | 2.31M | 666,000 | 1.48M | 2.04M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 163,000 | — | — | — | — |
| Non current assets | |||||
| Properties | 945,000 | 822,000 | 707,000 | 31,000 | 496,000 |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | — | — | — | — | 980,000 |
| Construction in progress | — | — | — | — | — |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -121,000 | -48,000 | -14,000 | -8,000 | -807,000 |
| Goodwill | 617,000 | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 617,000 | — | — | — | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | — | 2.96M | 23,000 | 2,000 | 894,000 |
| Total liabilities | 2.43M | 8.55M | 92.72M | 40.46M | 6.12M |
| Current liabilities | |||||
| Accounts payable | 759,000 | 1.66M | 1.79M | 1.22M | 5.63M |
| Accrued expenses | 921,000 | 1.65M | 639,000 | 840,000 | 6.86M |
| Short term debt | 237,000 | 230,000 | 3.62M | 2.56M | 495,000 |
| Deferred revenue | — | 283,000 | 1.46M | 3.52M | — |
| Tax payable | 4,000 | 174,000 | — | — | — |
| Pensions | 315,000 | 447,000 | 660,000 | — | — |
| Other current liabilities | — | — | — | — | — |
| Non current liabilities | |||||
| Long term debt | 37,000 | 251,000 | 5.41M | 7.46M | — |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | 83,000 | 87,000 | — |
| Other non current liabilities | — | — | — | 27,000 | — |
| Shareholders equity | |||||
| Common stock | 10,000 | 9,000 | 3,000 | 223,000 | 50,000 |
| Retained earnings | -131.30M | -76.94M | -42.26M | -22.01M | -480.53M |
| Other shareholders equity | 49,000 | 407,000 | — | — | — |
| Total shareholders equity | 230.76M | 272.89M | -31.27M | -14.05M | -480.48M |
| Additional paid in capital | 362.00M | 349.41M | 10.98M | 7.74M | 597.68M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Operating Activities | ||||
| Net Income | -54.37M | -34.68M | -20.24M | -1.07M |
| Depreciation | -6.81M | 319,000 | 213,000 | 6,000 |
| Deferred Taxes | — | — | — | — |
| Stock-Based Compensation | 9.24M | 5.84M | 2.83M | 3.54M |
| Other Non-Cash Items | — | 1.06M | 207,000 | 121,000 |
| Accounts Receivable | — | — | — | — |
| Accounts Payable | — | — | — | — |
| Other Assets & Liabilities | -3.12M | -1.28M | -2.52M | 6.96M |
| Operating Cash Flow | -55.05M | -28.75M | -19.52M | 9.56M |
| Investing Activities | ||||
| Capital Expenditures | -175,000 | -199,000 | -55,000 | — |
| Net Intangibles | — | — | — | — |
| Net Acquisitions | — | — | — | — |
| Purchase of Investments | -272.01M | — | — | — |
| Sale of Investments | 185.00M | — | — | — |
| Investing Cash Flow | -87.18M | -199,000 | -55,000 | — |
| Financing Activities | ||||
| Long-Term Debt Issuance | — | — | — | 5.00M |
| Long-Term Debt Payments | — | -8.68M | -1.82M | — |
| Other Financing Charges | — | 198.84M | — | — |
| Financing Cash Flow | — | 190.16M | 52.99M | 5.00M |
| Other Cash Details | ||||
| End Cash Position | 70.97M | 210.52M | 60.06M | 24.52M |
| Income Tax Paid | — | — | — | — |
| Interest Paid | — | 366,000 | 576,000 | 325,000 |
| Free Cash Flow | -59.44M | -40.28M | -17.62M | 9.07M |
Error: Invalid format in Holders JSON file.
Article
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions
ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. Neffy's early sales also beat expectations, which I think showcases how much of a blockbuster it could become over time. Neffy targets several segments within severe allergic reactions and could also become an OTC medication soon. In total, this is a multibillion-dollar TAM.
Feb 6, 2025
Article
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.
Jan 13, 2025
Article
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions
Jan 6, 2025
